We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Rws Holdings Plc | LSE:RWS | London | Ordinary Share | GB00BVFCZV34 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.20 | 1.85% | 176.20 | 176.80 | 177.80 | 178.00 | 170.60 | 170.60 | 314,136 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 733.8M | -27.7M | -0.0738 | -24.01 | 664.8M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/10/2012 08:34 | back to sleep | alter ego | |
12/10/2012 07:32 | v nice too | phillis | |
21/9/2012 10:53 | firming up | phillis | |
03/7/2012 17:00 | "European Union Patent We have in the past highlighted the European Union Patent ("the Unitary Patent") as a potential risk. In recent months it has become more evident that the European Union's ("EU") competitiveness committee and the legal committee of the European Parliament will seek to give final approval to plans for such a patent. If successful, the first EU patents could be granted in 2014. However, Spain and Italy continue to oppose and appeal against the Unitary Patent and professional opinion remains highly sceptical of the current proposal, especially with regard to jurisdiction. Until the litigation system is tried and tested, patent attorneys and corporates are expected to be reluctant to use the new system because it is too risky to lose patent rights across the whole of the EU by relying on untested legislation. Opinion suggests that it will take 'a decade' before the European Patent Court gains sufficient standing and establishes enough precedents for corporates to be comfortable with relying on it. We believe this means that innovators are going to take time to consider their options before using the new regime." The patent may be valid across the EU (i.e. less patents) but there will surely be a continued demand from their corporate clients for translation into their native languages? | jeffian | |
03/7/2012 16:50 | fewer languages | phillis | |
03/7/2012 12:52 | Does the EU patent still not need translation, or is it written in 'European'? | jeffian | |
03/7/2012 11:31 | more on European patent from DT today | phillis | |
07/6/2012 10:31 | They seem a bit blase about the EU patent coming in 2014. | wjccghcc | |
07/6/2012 10:23 | Agree : steady is the word. At least the Davda aquisition seems to make financial sense. | gj2 | |
07/6/2012 09:20 | not bad but looks like they need to consolidate Inovia to give the numbers a BIG kick Dividend increase very acceptable and will continue to be so at similar rates of increase steady as she goes | phillis | |
10/4/2012 16:18 | The 'Market Update' section looked like a specific contradiction of the recent comments about falling patent numbers! "On March 5, the World Intellectual Property Office (WIPO) published figures showing a 10.7% increase in the annual PCT filings to 181,900 from 164,316, setting a new record and demonstrating that procuring international patent rights has remained an integral part of many IP strategies despite the economic conditions. The European Patent Office also recently published figures showing that the total number of European patent filings increased by 3.7% to 244,437 in 2011 from 235,700 in 2010." | jeffian | |
10/4/2012 14:04 | mad professor type it seems also looks like they may be getting some cross over from Inovia clients | phillis | |
05/4/2012 14:21 | I couldn't be bothered to answer that one, Phillis! However, I think the issue is whether the reduction in overall patents relates to the 'Mad Professor' type or whether mainstream companies with real IP to protect are cutting back. I suspect it's the former - for example I can't see Big Pharma failing to patent their drugs and pursue those who make generic copies - and I trust the vast majority of RWS's clients fall into the latter category. | jeffian | |
05/4/2012 12:30 | THE point is that fewer patents being registered means fewer translations - back to remedial class I'm afraid | phillis | |
03/4/2012 21:31 | this is a translation company there are three centres for filing internationaly covered patents vis london, new york and munich accoringly all patents wishing to be registered above have to file in english, german and, of course french imo rws will continue to grow | cnx | |
03/4/2012 17:11 | for sure most of RWS's clients are corporate so maybe it does affect their part of the market much at all | phillis | |
03/4/2012 16:06 | I know of at least one listed company (SRT) that doesn't think patents are worthwhile despite having leading technology to protect. Small companies do not have the resources to fight prolonged battles in court against deep pocketed outfits with slick lawyers who can convince you black is really white. | alter ego | |
03/4/2012 15:25 | Yes, I saw that, Phillis, and wondered about the implications. I managed to convince myself that it probably related to the myriad small inventions that are patented by 'inventors' every day (indeed, the article refers specifically to smaller companies not having the resources to fight patent battles) whereas RWS is mainly working with big companies needing patent translations, but I have to say I'm not sure......... | jeffian | |
03/4/2012 14:32 | a bit of negative news on the market | phillis | |
08/3/2012 14:34 | Mr Andrew Brode is the life tenant of the trust and the Executive Chairman of the Group. | grahamburn | |
08/3/2012 14:07 | RBC Trustees (Guernsey) Limited hold 42% of RWS. presumably this for benefit of directors and senior staff. do the ultimate beneficiaries need to be identified? | cnx | |
02/3/2012 11:24 | onwards and ever upwards | phillis | |
20/2/2012 17:09 | new high! divis in the bank :-) | phillis | |
14/2/2012 09:59 | Any analysis of inovia? apad | apad |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions